Clinical Trial

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-09; most recent amendment 2025-10-31.
Status change: Not Yet Recruiting → Recruiting 2025-10-31
Trial Details
NCT Number NCT07025148
Lead Sponsor University of Florida
Conditions Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Enrollment 40 participants
Start Date 2025-10-01
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-04